Risk factors for quinolone-resistance in women presenting with Escherichia coli acute pyelonephritis

Medecine et Maladies Infectieuses

Volumn 44, Issue 5, 2014, Pages 206-216

  Bedoin, M ^a   Cazorla, C ^b   Lucht, F ^b   Berthelot, P ^b   Boyer, M ^c   Carricajo, A ^b   Guerin T ^c   Viallon, A ^b  

^a Centre Hospitalier de Saint Chamond   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c CHG de Roanne   (France)

Author keywords

Escherichia coli; Pyelonephritis; Quinolone resistance; Risk factors

Indexed keywords

C REACTIVE PROTEIN; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIURIA; COHORT ANALYSIS; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; EMERGENCY WARD; ESCHERICHIA COLI; FEMALE; FRANCE; HEALTH CARE FACILITY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LEUKOCYTURIA; LONG TERM CARE; MAJOR CLINICAL STUDY; NONHUMAN; POPULATION SIZE; PROSPECTIVE STUDY; RISK FACTOR; URINALYSIS; ADOLESCENT; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DRUG EFFECTS; EMERGENCY HEALTH SERVICE; ESCHERICHIA COLI INFECTIONS; HOSPITAL; INSTITUTIONALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PYELONEPHRITIS; RESIDENTIAL CARE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TEACHING HOSPITAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CATCHMENT AREA (HEALTH); COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EMERGENCY SERVICE, HOSPITAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; FRANCE; HOSPITALIZATION; HOSPITALS, TEACHING; HOSPITALS, URBAN; HUMANS; INSTITUTIONALIZATION; LONG-TERM CARE; MIDDLE AGED; NALIDIXIC ACID; OFLOXACIN; PYELONEPHRITIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84901980496     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2014.02.003     Document Type: Article

References (40)

1. Anonyme Etat des lieux. La résistance aux antibiotiques. La lettre de l'Institut de veille sanitaire. Prevalence 2004, 11:4-6.
2. Efstathiou S.P., Pefanis A.V., Tsioulos D.I., Zacharos I.D., Tsiakou A.G., Mitromaras A.G., et al. Acute pyelonephritis in adults. Prediction of mortality and failure of treatment. Arch Intern Med 2003, 163(10):1206-1212.
3. Anomyme Recommandations de bonne pratique. Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires chez l'adulte. Rapport de l'Agence française de sécurité sanitaire et des produits de santé 2008, [accédé le 30/09/2012]. http://www.infectiologie.com/site/consensus%20_recos.php.
4. e Réunion interdisciplinaire de chimiothérapie anti-infectieuse; Dec 2-3; Paris France 2010.
5. Ortega M., Marco F., Soriano A., Almela M., Martínez J.A., Muñoz A., et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009, 63(3):568-574.
6. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Socety for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52(5):e103-e120.
7. e Réunion interdisciplinaire de chimiothérapie anti-infectieuse; 2011 Dec 1-2; Paris, France 2011.
8. Van der Starre W.E., van Nieuwkoop C., Paltansing S., van't Wout J.W., Groeneveld G.H., Becker M.J., et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011, 66(3):650-656.
9. Colodner R., Kometiani I., Chazan B., Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E.coli. Infection 2008, 36(1):41-45.
10. Lee G., Cho Y.H., Shim B.S., Lee S.D. Risk factors for antimicrobial resistance among the Escherichia coli strains isolated for Korean patients with acute uncomplicated cystitis: a prospective and nationwide study. J Korean Med Sci 2010, 25(8):1205-1209.
11. e Réunion interdisciplinaire de chimiothérapie anti-infectieuse; 2010 Dec 2-3; Paris, France 2010.
12. Arslan H., Azap O.K., Ergönül O., Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005, 56(5):914-918. Urinary Tract Infection Study Group.
13. Lautenbach E., Fishman N.O., Bilker W.B., Castiglioni A., Metlay J.P., Edelstein P.H., et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002, 162(21):2469-2477.
14. Rattanaumpawan P., Tolomeo P., Bilker W.B., Fishman N.O., Lautenbach E., Rattanaumpawan P., et al. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect 2010, 76(4):324-327.
15. Ramakrishnan K., Scheid D.C. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician 2005, 71(5):933-942.
16. Matthews S.J., Lancaster J.W. Urinary tract infections in the elderly population. Am J Geriatr Pharmacother 2011, 9(5):286-309.
17. Sotto A., De Boever C.M., Fabbro-Peray P., Gouby A., Sirot D., Jourdan J. Risk factors for antibiotic-resistant Escherichia coli Isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol 2001, 39(2):438-444.
18. Anonyme Définition des infections associées aux soins. Rapport du Comité technique des infections nosocomiales et des infections liées aux soins 2007, Direction de l'hospitalisation et de l'organisation des soins, Direction générale de la santé, Ministère de la santé, de la jeunesse et des sports, [www.sante.gouv.fr/IMG/pdf/rapport_vcourte.pdf, accédé le 05/10/2012].
19. De Decker L. L'indice de co-morbidité de Charlson. Ann Gerontol 2009, 2(3):159-160.
20. Groupe transversal sepsis Mise au point. Prise en charge initiale des états septiques graves de l'adulte et de l'enfant. Reanimation 2007, 16:S1-S21.
21. Dussauze H., Bourgault I., Doleris L.M., Prinseau j, Baglin A., Hanslik T. Corticothérapie systémique et risque infectieux. Rev Med Interne 2007, 28(12):841-851.
22. Anonyme Recommandations 2010. Comité de l'antibiogramme de la Société francaise de microbiologie 2010, [accédé le 30/09/2012]. http://www.sfm-microbiologie.org/pages/%3Fidl=21%26page=746.
23. Péan Y., Goldstein F.W., De Bels F. Evolution de la sensibilité et épidémiologie de la résistance des entérobactéries de ville au cours des enquêtes Vigil'Roc. Med Mal Infect 2001, 31(10):609-628.
24. Bertaux A. Facteurs de résistance de Escherichia coli urinaire aux quinolones en médecine de soins primaires [thèse] 2010, Université de Nice Sophia-Antipolis, Nice.
25. Baquero F., Negri M.C., Morosini M.I., Blazquez J. Antibiotic-Selective Environments. Clin Infect Dis 1998, 27(Suppl. 1):S5-S11.
26. Chenia H.Y., Pillay B., Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother 2006, 58(6):1274-1278.
27. e Réunion interdisciplinaire de chimiothérapie anti-infectieuse; 2010 Dec 2-3; Paris, France 2010.
28. Richard P., Delangle M.H., Merrien D., Barillé S., Reynaud A., Minozzi C., et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association?. Clin Infect Dis 1994, 19(1):54-59.
29. Muder R.R., Brennen C., Goetz A.M., Wagener M.M., Rihs J.D. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991, 35(2):256-258.
30. McGregor J.C., Kim P.W., Perencevich E.N., Bradham D.D., Furuno J.P., Kaye K.S., et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol 2005, 161(5):483-493.
31. Batard E, Montassier E, Ballereau F, Potel G. De la consommation d'antibiotiques aux résistances bactériennes: l'exemple de la résistance d'Escherichia coli aux quinolones. 2011; 17(4):294-301.
32. Colodner R., Rock W., Chazan B., Keller N., Guy N., Sakran W., et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004, 23(3):163-167.
33. Anonyme Résultats du recensement de la population. Institut National de la Statistique et des Etudes Economiques 2009, [accédé le 05/10/2012]. http://recensement.insee.fr/home.action.
34. Garau J., Xercavins M., Rodriguez-Carballeira M., Gómez-Vera J.R., Coll I., Vidal D., et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999, 43(11):2736-2741.
35. Murray B.E., Mathewson J.J., DuPont H.L., Ericsson C.D., Reves R.R. Emergence of resistant fecal Escherichia coli in travelers not taking prophylactic antimicrobial agents. Antimicrob Agents Chemother 1990, 34(4):515-518.
36. Vincent C., Boerlin P., Daignault D., Dozois C.M., Dutil L., Galanakis C., et al. Food reservoir for Escherichia coli causing urinary tract infections. Emerg Infect Dis 2010, 16(1):88-95.
37. Galperine T. Mise en perspectives: recommandations AFSSAPS pour le traitement des infections urinaires communautaires et données des réseaux de l'ONERBA. 11(Journées Nationales d'Infectiologie; 9-11 juin 2010; Montpellier, France. 2010, [www.onerba.org/IMG/pdf/JNI2010_IUrinaires_TG.pdf, accédé le 05/10/2012]. E. Delaporte (Ed.).
38. Anonyme Plan national d'alerte sur les antibiotiques 2011-2016 2011, Ministère du travail, de l'Emploi et de la Santé, [http://www.sante.gouv.fr/IMG/pdf/plan_antibiotiques _2011-2016_DEFINITIF.pdf, accédé le 05/10/2012].
39. Butler C.C., Dunstan F., Heginbothom M., Mason B., Roberts Z., et al. Containing antibiotic prescribing: decreased antibiotic-resistant coliform urinary tract infections with reduction in antibiotic prescribing by general practices. Br J Gen Pract 2007, 57(543):785-792.
40. Ferech M., Coenen S., Malhotra-Kumar S., Dvorakova K., Hendrickx E., Suetens C. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006, 58(2):423-427.